OPEN END-TURBO-OPTIONSSCHEIN - GILEAD SCIENCES | Market Closed - BOERSE MUENCHEN 01:05:57 22/06/2024 am IST | ||
| 12.89 EUR | +16.97% |
|
| Current month | +104.60% | ||
| 1 month | +33.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 12.89 | +16.97% |
| 20/24/20 | 11.02 | +79.48% |
| 19/24/19 | 6.14 | +5.14% |
| 18/24/18 | 5.84 | -20.87% |
| 17/24/17 | 7.38 | -4.16% |
Real-time BOERSE MUENCHEN
Last update June 22, 2024 at 01:05 am IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | HSBC |
| WKN | TT4Q9H |
| ISIN | DE000TT4Q9H8 |
| Date issued | 11/11/2020 |
| Strike | 56.84 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 5.9 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.72 € |
|---|---|
| Lowest since issue | 4 € |
| Spread | 0.08 € |
| Spread % | 0.62% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.67
USD
Average target price
82.7
USD
Spread / Average Target
+17.02%
- Stock Market
- Certificates
- Certificat
